Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455546 · ClinicalTrials.gov registry record · Phase 2
PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease
A Phase 2 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00455546 is a Phase 2 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 400 participants.
The verdict
NCT00455546, a Phase 2 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The study will be conducted at up to 80 centers worldwide and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD). Subjects will be randomized to receive either placebo tablets or one of 4 orally active doses of A-002. The duration of study drug therapy will be 8 weeks.
Interventions
- DRUG A-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455546
The ClinicalTrials.gov registry entry for NCT00455546 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A-002 is the first listed.
NCT00455546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00455546 about?
NCT00455546 is a clinical study titled "PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease". The study will be conducted at up to 80 centers worldwide and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD). Subjects will be randomized to receive either placebo tablets or one of 4 orally active doses of A-002. Th...
What is the current status of trial NCT00455546?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2007-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00455546?
The interventions under investigation include: A-002 (DRUG).
Who is sponsoring clinical trial NCT00455546?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.